De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
TG Therapeutics Toekomstige groei
Future criteriumcontroles 6/6
TG Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 43.5% en 28.4% per jaar. De winst per aandeel zal naar verwachting groeien met 41.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 46.7% zijn.
Belangrijke informatie
43.5%
Groei van de winst
41.9%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.9% |
| Inkomstengroei | 28.4% |
| Toekomstig rendement op eigen vermogen | 46.7% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 18 Sep 2024 |
Recente toekomstige groei-updates
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09
TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04Recent updates
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 640 | 225 | 270 | 205 | 5 |
| 12/31/2025 | 495 | 135 | 168 | 144 | 8 |
| 12/31/2024 | 328 | 27 | 9 | -19 | 8 |
| 6/30/2024 | 347 | 96 | 68 | 68 | N/A |
| 3/31/2024 | 289 | 41 | 20 | 20 | N/A |
| 12/31/2023 | 234 | 13 | -31 | -31 | N/A |
| 9/30/2023 | 190 | -26 | -42 | -42 | N/A |
| 6/30/2023 | 24 | -176 | -160 | -160 | N/A |
| 3/31/2023 | 9 | -169 | -167 | -167 | N/A |
| 12/31/2022 | 3 | -198 | -176 | -176 | N/A |
| 9/30/2022 | 5 | -239 | -239 | -239 | N/A |
| 6/30/2022 | 7 | -288 | -272 | -272 | N/A |
| 3/31/2022 | 8 | -326 | -283 | -283 | N/A |
| 12/31/2021 | 7 | -348 | -296 | -296 | N/A |
| 9/30/2021 | 4 | -343 | -261 | -261 | N/A |
| 6/30/2021 | 2 | -345 | -251 | -250 | N/A |
| 3/31/2021 | 1 | -319 | -234 | -234 | N/A |
| 12/31/2020 | 0 | -279 | -215 | -215 | N/A |
| 9/30/2020 | 0 | -231 | -193 | -193 | N/A |
| 6/30/2020 | 0 | -206 | -170 | -170 | N/A |
| 3/31/2020 | 0 | -189 | -162 | -162 | N/A |
| 12/31/2019 | 0 | -173 | -133 | -133 | N/A |
| 9/30/2019 | 0 | -187 | -136 | -136 | N/A |
| 6/30/2019 | 0 | -159 | -136 | -136 | N/A |
| 3/31/2019 | 0 | -167 | -134 | -134 | N/A |
| 12/31/2018 | 0 | -173 | -129 | -129 | N/A |
| 9/30/2018 | 0 | -150 | -117 | -117 | N/A |
| 6/30/2018 | 0 | -148 | -107 | -107 | N/A |
| 3/31/2018 | 0 | -132 | N/A | -100 | N/A |
| 12/31/2017 | 0 | -118 | N/A | -94 | N/A |
| 9/30/2017 | 0 | -111 | N/A | -89 | N/A |
| 6/30/2017 | 0 | -105 | N/A | -81 | N/A |
| 3/31/2017 | 0 | -92 | N/A | -67 | N/A |
| 12/31/2016 | 0 | -78 | N/A | -62 | N/A |
| 9/30/2016 | 0 | -72 | N/A | -57 | N/A |
| 6/30/2016 | 0 | -61 | N/A | -53 | N/A |
| 3/31/2016 | 0 | -62 | N/A | -52 | N/A |
| 12/31/2015 | 0 | -63 | N/A | -45 | N/A |
| 9/30/2015 | 0 | -64 | N/A | -47 | N/A |
| 6/30/2015 | 0 | -68 | N/A | -44 | N/A |
| 3/31/2015 | 0 | -63 | N/A | -36 | N/A |
| 12/31/2014 | 0 | -56 | N/A | -35 | N/A |
| 9/30/2014 | 0 | -43 | N/A | -25 | N/A |
| 6/30/2014 | 0 | -30 | N/A | -18 | N/A |
| 3/31/2014 | 0 | -24 | N/A | -17 | N/A |
| 12/31/2013 | 0 | -20 | N/A | -11 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei TGTX ( 43.5% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van TGTX ( 43.5% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).
Hoge groeiwinsten: De winst van TGTX zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van TGTX ( 28.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van TGTX ( 28.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen TGTX zal naar verwachting over 3 jaar zeer hoog zijn ( 46.7 %).